SSC-SYSTEMIC SCLEROSIS
Clinical trials for SSC-SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SSC-SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for SSC-SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tiny early trial launches for new autoimmune drug
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfen…
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Sponsor: University of Patras • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to other therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack the disease. The main …
Matched conditions: SSC-SYSTEMIC SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC